These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 29045347)

  • 1. Reduction of Recurrence Risk of Pancreatitis in Cystic Fibrosis With Ivacaftor: Case Series.
    Carrion A; Borowitz DS; Freedman SD; Siracusa CM; Goralski JL; Hadjiliadis D; Srinivasan S; Stokes DC
    J Pediatr Gastroenterol Nutr; 2018 Mar; 66(3):451-454. PubMed ID: 29045347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of CFTR modulators on a cystic fibrosis patient presenting with recurrent pancreatitis in the absence of respiratory symptoms: a case report.
    Johns JD; Rowe SM
    BMC Gastroenterol; 2019 Jul; 19(1):123. PubMed ID: 31296159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
    McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
    Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ivacaftor-treated Patients with Cystic Fibrosis Derive Long-Term Benefit Despite No Short-Term Clinical Improvement.
    Heltshe SL; Rowe SM; Skalland M; Baines A; Jain M;
    Am J Respir Crit Care Med; 2018 Jun; 197(11):1483-1486. PubMed ID: 29256624
    [No Abstract]   [Full Text] [Related]  

  • 5. Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor.
    Bessonova L; Volkova N; Higgins M; Bengtsson L; Tian S; Simard C; Konstan MW; Sawicki GS; Sewall A; Nyangoma S; Elbert A; Marshall BC; Bilton D
    Thorax; 2018 Aug; 73(8):731-740. PubMed ID: 29748252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis.
    Suthoff ED; Bonafede M; Limone B; O'Callaghan L; Sawicki GS; Wagener JS
    J Med Econ; 2016 Sep; 19(9):845-51. PubMed ID: 27074519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in Lung Clearance Index in Preschool-aged Patients with Cystic Fibrosis Treated with Ivacaftor (GOAL): A Clinical Trial.
    Ratjen F; Klingel M; Black P; Powers MR; Grasemann H; Solomon M; Sagel SD; Donaldson SH; Rowe SM; Rosenfeld M
    Am J Respir Crit Care Med; 2018 Aug; 198(4):526-528. PubMed ID: 29614238
    [No Abstract]   [Full Text] [Related]  

  • 8. Ivacaftor for the p.Ser549Arg (S549R) gating mutation - The Israeli experience.
    Dagan A; Cohen-Cymberknoh M; Shteinberg M; Levine H; Vilozni D; Bezalel Y; Bar Aluma BE; Sarouk I; Ashkenazi M; Lavie M; Tsabari R; Blau H; Kerem E; Bentur L; Efrati O; Livnat G
    Respir Med; 2017 Oct; 131():225-228. PubMed ID: 28947035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G551D mutation: a review.
    Dryden C; Wilkinson J; Young D; Brooker RJ;
    Arch Dis Child; 2018 Jan; 103(1):68-70. PubMed ID: 27288428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ivacaftor in cystic fibrosis adults: Czech experience with six years of follow-up.
    Fila L; Valentova Bartakova L; Grandcourtova A; Marel M; Drnek R; Bilkova A; Macek M; Drevinek P
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Jun; 160(2):276-9. PubMed ID: 27226150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor.
    Munce D; Lim M; Akong K
    Pediatr Pulmonol; 2020 Dec; 55(12):3381-3383. PubMed ID: 32910556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy.
    Guerra L; D'Oria S; Favia M; Castellani S; Santostasi T; Polizzi AM; Mariggiò MA; Gallo C; Casavola V; Montemurro P; Leonetti G; Manca A; Conese M
    Pediatr Pulmonol; 2017 Jul; 52(7):900-908. PubMed ID: 28445004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restoration of exocrine pancreatic function in older children with cystic fibrosis on ivacaftor.
    Nichols AL; Davies JC; Jones D; Carr SB
    Paediatr Respir Rev; 2020 Sep; 35():99-102. PubMed ID: 32386958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cystic Fibrosis-related Diabetes Is Associated with Worse Lung Function Trajectory despite Ivacaftor Use.
    Bengtson CD; He J; Kim MD; Salathe MA
    Am J Respir Crit Care Med; 2021 Dec; 204(11):1343-1345. PubMed ID: 34469275
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic benefit of ivacaftor in late cystic fibrosis caused by homozygous IVS8-5T CFTR polymorphism.
    Magne F; Durupt S; Nove-Josserand R; Bey-Omar F; Laoust L; Cottin V; Durieu I; Reynaud Q
    J Cyst Fibros; 2017 Jan; 16(1):89-90. PubMed ID: 27810230
    [No Abstract]   [Full Text] [Related]  

  • 16. Ivacaftor and Airway Inflammation in Preschool Children with Cystic Fibrosis.
    McNally P; Butler D; Karpievitch YV; Linnane B; Ranganathan S; Stick SM; Hall GL; Schultz A
    Am J Respir Crit Care Med; 2021 Sep; 204(5):605-608. PubMed ID: 34077699
    [No Abstract]   [Full Text] [Related]  

  • 17. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.
    Heltshe SL; Mayer-Hamblett N; Burns JL; Khan U; Baines A; Ramsey BW; Rowe SM;
    Clin Infect Dis; 2015 Mar; 60(5):703-12. PubMed ID: 25425629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.
    Talamo Guevara M; McColley SA
    Expert Opin Drug Saf; 2017 Nov; 16(11):1305-1311. PubMed ID: 28846049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world use of ivacaftor in Canada: A retrospective analysis using the Canadian Cystic Fibrosis Registry.
    Kawala CR; Ma X; Sykes J; Stanojevic S; Coriati A; Stephenson AL
    J Cyst Fibros; 2021 Nov; 20(6):1040-1045. PubMed ID: 33810992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Energy Balance and Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic Fibrosis Gating Mutations.
    Stallings VA; Sainath N; Oberle M; Bertolaso C; Schall JI
    J Pediatr; 2018 Oct; 201():229-237.e4. PubMed ID: 30029855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.